Cargando…

International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship

BACKGROUND: In this international multicenter study, we aimed to determine the independent risk factors associated with increased 30 day mortality and the impact of cancer and novel treatment modalities in a large group of patients with and without cancer with COVID-19 from multiple countries. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Raad, Issam I, Hachem, Ray, Masayuki, Nigo, Datoguia, Tarcila, Dagher, Hiba, Jiang, Ying, Subbiah, Vivek, Siddiqui, Bilal, Bayle, Arnaud, Somer, Robert, Fernández Cruz, Ana, Gorak, Edward, Bhinder, Arvinder, Mori, Nobuyoshi, Hamerschlak, Nelson, Shelanski, Samuel, Dragovich, Tomislav, Vong Kiat, Yee Elise, Fakhreddine, Suha, Pierre, Abi Hanna, Chemaly, Roy F, Mulanovich, Victor, Adachi, Javier, Borjan, Jovan, Khawaja, Fareed, Granwehr, Bruno, John, Teny, Yepez, Eduardo Yepez, Torres, Harrys A, Ammakkanavar, Natraj Reddy, Yibirin, Marcel, Reyes-Gibby, Cielito C, Pande, Mala, Ali, Noman, Rojo, Raniv Dawey, Ali, Shahnoor M, Deeba, Rita E, Chaftari, Patrick, Matsuo, Takahiro, Ishikawa, Kazuhiro, Hasegawa, Ryo, Aguado-Noya, Ramón, García, Alvaro Garcia, Puchol, Cristina Traseira, Lee, Dong Gun, Slavin, Monica, Teh, Benjamin, Arias, Cesar A, Kontoyiannis, Dimitrios P, Malek, Alexandre E, Chaftari, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981148/
https://www.ncbi.nlm.nih.gov/pubmed/36715684
http://dx.doi.org/10.7554/eLife.81127
_version_ 1784900041123561472
author Raad, Issam I
Hachem, Ray
Masayuki, Nigo
Datoguia, Tarcila
Dagher, Hiba
Jiang, Ying
Subbiah, Vivek
Siddiqui, Bilal
Bayle, Arnaud
Somer, Robert
Fernández Cruz, Ana
Gorak, Edward
Bhinder, Arvinder
Mori, Nobuyoshi
Hamerschlak, Nelson
Shelanski, Samuel
Dragovich, Tomislav
Vong Kiat, Yee Elise
Fakhreddine, Suha
Pierre, Abi Hanna
Chemaly, Roy F
Mulanovich, Victor
Adachi, Javier
Borjan, Jovan
Khawaja, Fareed
Granwehr, Bruno
John, Teny
Yepez, Eduardo Yepez
Torres, Harrys A
Ammakkanavar, Natraj Reddy
Yibirin, Marcel
Reyes-Gibby, Cielito C
Pande, Mala
Ali, Noman
Rojo, Raniv Dawey
Ali, Shahnoor M
Deeba, Rita E
Chaftari, Patrick
Matsuo, Takahiro
Ishikawa, Kazuhiro
Hasegawa, Ryo
Aguado-Noya, Ramón
García, Alvaro Garcia
Puchol, Cristina Traseira
Lee, Dong Gun
Slavin, Monica
Teh, Benjamin
Arias, Cesar A
Kontoyiannis, Dimitrios P
Malek, Alexandre E
Chaftari, Anne-Marie
author_facet Raad, Issam I
Hachem, Ray
Masayuki, Nigo
Datoguia, Tarcila
Dagher, Hiba
Jiang, Ying
Subbiah, Vivek
Siddiqui, Bilal
Bayle, Arnaud
Somer, Robert
Fernández Cruz, Ana
Gorak, Edward
Bhinder, Arvinder
Mori, Nobuyoshi
Hamerschlak, Nelson
Shelanski, Samuel
Dragovich, Tomislav
Vong Kiat, Yee Elise
Fakhreddine, Suha
Pierre, Abi Hanna
Chemaly, Roy F
Mulanovich, Victor
Adachi, Javier
Borjan, Jovan
Khawaja, Fareed
Granwehr, Bruno
John, Teny
Yepez, Eduardo Yepez
Torres, Harrys A
Ammakkanavar, Natraj Reddy
Yibirin, Marcel
Reyes-Gibby, Cielito C
Pande, Mala
Ali, Noman
Rojo, Raniv Dawey
Ali, Shahnoor M
Deeba, Rita E
Chaftari, Patrick
Matsuo, Takahiro
Ishikawa, Kazuhiro
Hasegawa, Ryo
Aguado-Noya, Ramón
García, Alvaro Garcia
Puchol, Cristina Traseira
Lee, Dong Gun
Slavin, Monica
Teh, Benjamin
Arias, Cesar A
Kontoyiannis, Dimitrios P
Malek, Alexandre E
Chaftari, Anne-Marie
author_sort Raad, Issam I
collection PubMed
description BACKGROUND: In this international multicenter study, we aimed to determine the independent risk factors associated with increased 30 day mortality and the impact of cancer and novel treatment modalities in a large group of patients with and without cancer with COVID-19 from multiple countries. METHODS: We retrospectively collected de-identified data on a cohort of patients with and without cancer diagnosed with COVID-19 between January and November 2020 from 16 international centers. RESULTS: We analyzed 3966 COVID-19 confirmed patients, 1115 with cancer and 2851 without cancer patients. Patients with cancer were more likely to be pancytopenic and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding 2 wk (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin, and procalcitonin) but were less likely to present with clinical symptoms (p≤0.01). By country-adjusted multivariable logistic regression analyses, cancer was not found to be an independent risk factor for 30 day mortality (p=0.18), whereas lymphopenia was independently associated with increased mortality in all patients and in patients with cancer. Older age (≥65y) was the strongest predictor of 30 day mortality in all patients (OR = 4.47, p<0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30 day mortality (OR = 0.64, p=0.036). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30 day mortality rate than those who did not (5.9 vs 17.6%; p=0.03). CONCLUSIONS: Increased 30 day all-cause mortality from COVID-19 was not independently associated with cancer but was independently associated with lymphopenia often observed in hematolgic malignancy. Remdesivir, particularly in patients with cancer receiving low-flow oxygen, can reduce 30 day all-cause mortality. FUNDING: National Cancer Institute and National Institutes of Health.
format Online
Article
Text
id pubmed-9981148
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-99811482023-03-03 International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship Raad, Issam I Hachem, Ray Masayuki, Nigo Datoguia, Tarcila Dagher, Hiba Jiang, Ying Subbiah, Vivek Siddiqui, Bilal Bayle, Arnaud Somer, Robert Fernández Cruz, Ana Gorak, Edward Bhinder, Arvinder Mori, Nobuyoshi Hamerschlak, Nelson Shelanski, Samuel Dragovich, Tomislav Vong Kiat, Yee Elise Fakhreddine, Suha Pierre, Abi Hanna Chemaly, Roy F Mulanovich, Victor Adachi, Javier Borjan, Jovan Khawaja, Fareed Granwehr, Bruno John, Teny Yepez, Eduardo Yepez Torres, Harrys A Ammakkanavar, Natraj Reddy Yibirin, Marcel Reyes-Gibby, Cielito C Pande, Mala Ali, Noman Rojo, Raniv Dawey Ali, Shahnoor M Deeba, Rita E Chaftari, Patrick Matsuo, Takahiro Ishikawa, Kazuhiro Hasegawa, Ryo Aguado-Noya, Ramón García, Alvaro Garcia Puchol, Cristina Traseira Lee, Dong Gun Slavin, Monica Teh, Benjamin Arias, Cesar A Kontoyiannis, Dimitrios P Malek, Alexandre E Chaftari, Anne-Marie eLife Medicine BACKGROUND: In this international multicenter study, we aimed to determine the independent risk factors associated with increased 30 day mortality and the impact of cancer and novel treatment modalities in a large group of patients with and without cancer with COVID-19 from multiple countries. METHODS: We retrospectively collected de-identified data on a cohort of patients with and without cancer diagnosed with COVID-19 between January and November 2020 from 16 international centers. RESULTS: We analyzed 3966 COVID-19 confirmed patients, 1115 with cancer and 2851 without cancer patients. Patients with cancer were more likely to be pancytopenic and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding 2 wk (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin, and procalcitonin) but were less likely to present with clinical symptoms (p≤0.01). By country-adjusted multivariable logistic regression analyses, cancer was not found to be an independent risk factor for 30 day mortality (p=0.18), whereas lymphopenia was independently associated with increased mortality in all patients and in patients with cancer. Older age (≥65y) was the strongest predictor of 30 day mortality in all patients (OR = 4.47, p<0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30 day mortality (OR = 0.64, p=0.036). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30 day mortality rate than those who did not (5.9 vs 17.6%; p=0.03). CONCLUSIONS: Increased 30 day all-cause mortality from COVID-19 was not independently associated with cancer but was independently associated with lymphopenia often observed in hematolgic malignancy. Remdesivir, particularly in patients with cancer receiving low-flow oxygen, can reduce 30 day all-cause mortality. FUNDING: National Cancer Institute and National Institutes of Health. eLife Sciences Publications, Ltd 2023-01-30 /pmc/articles/PMC9981148/ /pubmed/36715684 http://dx.doi.org/10.7554/eLife.81127 Text en © 2023, Raad, Hachem et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Medicine
Raad, Issam I
Hachem, Ray
Masayuki, Nigo
Datoguia, Tarcila
Dagher, Hiba
Jiang, Ying
Subbiah, Vivek
Siddiqui, Bilal
Bayle, Arnaud
Somer, Robert
Fernández Cruz, Ana
Gorak, Edward
Bhinder, Arvinder
Mori, Nobuyoshi
Hamerschlak, Nelson
Shelanski, Samuel
Dragovich, Tomislav
Vong Kiat, Yee Elise
Fakhreddine, Suha
Pierre, Abi Hanna
Chemaly, Roy F
Mulanovich, Victor
Adachi, Javier
Borjan, Jovan
Khawaja, Fareed
Granwehr, Bruno
John, Teny
Yepez, Eduardo Yepez
Torres, Harrys A
Ammakkanavar, Natraj Reddy
Yibirin, Marcel
Reyes-Gibby, Cielito C
Pande, Mala
Ali, Noman
Rojo, Raniv Dawey
Ali, Shahnoor M
Deeba, Rita E
Chaftari, Patrick
Matsuo, Takahiro
Ishikawa, Kazuhiro
Hasegawa, Ryo
Aguado-Noya, Ramón
García, Alvaro Garcia
Puchol, Cristina Traseira
Lee, Dong Gun
Slavin, Monica
Teh, Benjamin
Arias, Cesar A
Kontoyiannis, Dimitrios P
Malek, Alexandre E
Chaftari, Anne-Marie
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
title International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
title_full International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
title_fullStr International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
title_full_unstemmed International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
title_short International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
title_sort international multicenter study comparing covid-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981148/
https://www.ncbi.nlm.nih.gov/pubmed/36715684
http://dx.doi.org/10.7554/eLife.81127
work_keys_str_mv AT raadissami internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT hachemray internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT masayukinigo internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT datoguiatarcila internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT dagherhiba internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT jiangying internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT subbiahvivek internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT siddiquibilal internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT baylearnaud internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT somerrobert internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT fernandezcruzana internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT gorakedward internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT bhinderarvinder internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT morinobuyoshi internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT hamerschlaknelson internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT shelanskisamuel internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT dragovichtomislav internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT vongkiatyeeelise internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT fakhreddinesuha internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT pierreabihanna internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT chemalyroyf internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT mulanovichvictor internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT adachijavier internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT borjanjovan internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT khawajafareed internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT granwehrbruno internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT johnteny internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT yepezeduardoyepez internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT torresharrysa internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT ammakkanavarnatrajreddy internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT yibirinmarcel internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT reyesgibbycielitoc internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT pandemala internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT alinoman internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT rojoranivdawey internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT alishahnoorm internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT deebaritae internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT chaftaripatrick internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT matsuotakahiro internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT ishikawakazuhiro internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT hasegawaryo internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT aguadonoyaramon internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT garciaalvarogarcia internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT pucholcristinatraseira internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT leedonggun internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT slavinmonica internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT tehbenjamin internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT ariascesara internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT kontoyiannisdimitriosp internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT malekalexandree internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship
AT chaftariannemarie internationalmulticenterstudycomparingcovid19inpatientswithcancertopatientswithoutcancerimpactofriskfactorsandtreatmentmodalitiesonsurvivorship